Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology

Authors, Journal, Affiliations, Type, DOI

• Michael G. Fradley MD (Vice Chair), Theresa M. Beckie PhD, Sherry Ann Brown MD PhD, Richard K. Cheng MD, Susan F. Dent MD, Anju Nohria MD, Kristen K. Patton MD, Jagmeet P. Singh MD DPhil, Brian Olshansky MD (Chair); on behalf of the AHA Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular and Stroke Nursing
• Circulation. 2021;144:e41–e55
• AHA Scientific Statement
• DOI: 10.1161/CIR.0000000000000986

Overview

This AHA Scientific Statement comprehensively reviews arrhythmias and autonomic disorders in patients with cancer and cancer survivors. It covers the full spectrum — atrial fibrillation (most common), QT prolongation and ventricular arrhythmias, bradyarrhythmias, and autonomic dysfunction — across all major cancer drug classes, with management algorithms for AF rate/rhythm control, anticoagulation, QT monitoring, ICD/CRT indications, and autonomic rehabilitation. Unique challenges include cancer-specific drug-drug interactions, thrombocytopenia complicating anticoagulation decisions, and limitations of standard risk scores (CHA₂DS₂-VASc, HAS-BLED) in cancer populations.

Keywords

AHA Scientific Statements; antiarrhythmic agents; anticoagulants; arrhythmias, cardiac; cardiotoxicity; medical oncology

Key Takeaways

Cancer Therapeutics Associated with Arrhythmias

• Arrhythmic complications occur with cytotoxic chemotherapies, targeted agents, and novel immunotherapies including checkpoint inhibitors and CAR-T cell therapy; AF is the most common arrhythmia, but QT prolongation, ventricular arrhythmias, and bradyarrhythmias also occur.
• Pathophysiology varies: direct cellular effects, electrolyte abnormalities, or secondary cardiotoxicity (HF, ischaemia, myocarditis).

Atrial Fibrillation and Other Atrial Arrhythmias

Epidemiology

• The cancer–AF relationship is bidirectional: patients with cancer have higher AF incidence, and AF patients have higher cancer incidence (shared risk factors including advanced age, inflammation, metabolic disorders).
• A study of >15,000 patients confirmed higher prevalent AF in cancer patients vs. non-cancer controls.

Drug-specific AF incidence

• Anthracyclines (doxorubicin-containing regimens): AF in 10.3% of 29 patients treated; in anthracycline-associated LV dysfunction, AF burden up to 56.6%.
• Melphalan / HSCT: 5.1% atrial arrhythmias overall; melphalan-based regimens had 11.0% supraventricular arrhythmias vs. non-melphalan regimens. New-onset atrial arrhythmias post-HSCT correlate with all-cause mortality at 1 year.
• Ibrutinib (BTK inhibitor): AF incidence 3.5–16% across 16 studies; rate 5.8 per 100 person-years. Meta-analysis of 8 RCTs (n=2580): relative risk 4.69 (95% CI 2.17–7.64, P<0.001). Mechanism: BTK/Tec kinase/PI3K inhibition; enhanced sarcoplasmic reticulum calcium automaticity. Newer BTKi (acalabrutinib 4.1%, zanubrutinib 2%) have lower AF rates due to higher BTK selectivity.
• ICI (checkpoint inhibitors): 25.7% AF/flutter in ICI-associated myocarditis; 30% AF in ICI-related cardiotoxicity — underlying myocarditis drives arrhythmia risk.
• CAR-T cell therapy: AF in 7.5% and SVT in 1 patient (retrospective 145-patient series); cytokine release syndrome likely mechanism.
• VEGFi (sorafenib + 5-FU): 5.1% AF in small series (n=39).
• Ponatinib (BCR-ABL TKI 3rd gen): AF up to 7% (phase 2) to 1.9% (phase 3 trial); disparity unexplained.

Management of AF — Rate and Rhythm Control

• Follow general population algorithms with special consideration for drug-drug interactions (cytochrome P450 3A4, P450 2D6, P-glycoprotein).
• Rate control: Goal resting HR <110 bpm; β-blockers preferred.
  • Nondihydropyridine CCBs (diltiazem/verapamil): caution — inhibit CYP3A4 → increased cancer drug concentrations.
  • Digoxin: caution — many cancer drugs (e.g. ibrutinib) inhibit P-glycoprotein → increased digoxin toxicity.
  • Imatinib/abiraterone: inhibit CYP2D6 → increased β-blocker (metoprolol/carvedilol) concentrations.
  • Dronedarone: avoid — CYP3A4 + P-glycoprotein effects.
  • Amiodarone: frequently used but increases cancer drug concentrations via same metabolic pathways.
• Rhythm control: EAST-AFNET 4 demonstrated early rhythm control benefits but cancer patients were excluded; cardioversion may lack long-term durability in the cancer inflammatory milieu.
• Catheter ablation: Potential strategy but procedural success in cancer-related arrhythmias is not established.

Anticoagulation and Thrombosis Prevention

• Stroke risk scoring: CHA₂DS₂-VASc recommended (men ≥2, women ≥3 for anticoagulation) but may not be accurate in cancer patients who have additional risk factors not captured by the score.
• Bleeding risk scoring: HAS-BLED does not account for thrombocytopenia or intracranial metastases — not reliable in cancer populations; cancer-specific risk algorithms are needed.
• DOACs preferred over warfarin for non-valvular AF (per AHA/ACC/HRS 2019); ARISTOTLE subgroup (n=1236 cancer patients) confirmed apixaban superior to warfarin for stroke/systemic embolism; similar results with edoxaban (ENGAGE AF-TIMI 48).
• Drug-drug interactions with DOACs: All DOACs interact with P-glycoprotein; dabigatran most affected. Rivaroxaban/apixaban metabolised by CYP3A4 — caution with ibrutinib (CYP3A4 inducer).
• Aspirin: No longer recommended for AF-related thromboembolism prevention; higher risk in cancer due to thrombocytopenia and ibrutinib-related platelet dysfunction.
• LAAO devices: No cancer-specific trial data; device-related thrombus risk may be increased in hypercoagulable state.

QT Prolongation

• Incidence of QT prolongation in cancer: up to 22% across drug classes; arsenic trioxide highest at 26–93% (used in acute promyelocytic leukaemia).
• QT-prolonging mechanisms: direct K⁺ channel blockade; PI3K signalling inhibition (many TKIs) → ventricular repolarization delay.
• QTcF (Fridericia formula) preferred in cancer patients over Bazett — more accurate at heart rate extremes.
• Arrhythmic risk threshold: QTc >500 ms or change from baseline >60 ms.
• Monitoring: No standardised protocol — rely on drug-label instructions; novel therapeutics require ECG after first dose and each dose change; standardised QT-monitoring protocols are urgently needed.
• Management: Discontinue non-essential QT-prolonging drugs; correct electrolytes (K⁺, Mg²⁺); counsel patients on symptoms (presyncope, syncope, palpitations).
• Torsades de pointes treatment: IV magnesium sulfate; maintain HR >100 bpm (isoproterenol or temporary pacing); lidocaine + ACLS for refractory cases; mexiletine emerging data for arsenic-induced QT prolongation.
• Life-threatening arrhythmias remain rare (<1%) — decisions to withhold cancer therapy should involve oncology/cardiology/patient collaboration.

Ventricular Arrhythmias

• Chemotherapy-induced sustained VT/VF is relatively rare; higher incidence in advanced metastatic disease.
• Anthracyclines: VA risk secondary to LV systolic dysfunction; prevalence similar to non-cancer cardiomyopathies.
• Ibrutinib: Associated with VA independent of QT prolongation — may actually shorten QT; enhanced automaticity/triggered activity are the proposed mechanism.
• ICD criteria in chemo-induced cardiomyopathy: Standard guidelines apply — LVEF ≤35%, NYHA II–III, life expectancy >1 year.
• CRT in chemo-induced cardiomyopathy: MADIT-CHIC trial (single-arm, LVEF ≤35% + LBBB, median QRS 152 ms) demonstrated significant improvement in LVEF, LV volumes, LA volume, and HF symptoms at 6 months. CRT-pacemaker appropriate even for life expectancy <1 year for symptom control.

Bradyarrhythmias and Heart Block

• Paclitaxel: Reversible asymptomatic sinus bradycardia in up to 30%; advanced bradyarrhythmias atypical.
• Thalidomide: Sinus bradycardia in up to 40%; some patients require pacemaker.
• 5-Fluorouracil: Symptomatic sinus bradycardia in ~12% (one series); systematic review suggests lower clinically significant incidence.
• Ibrutinib: 2.3% conduction defects; 42% of which were high-grade/complete AV block; 18% fatal.
• Crizotinib/ceritinib (ALK inhibitors): Bradycardia common; symptomatic episodes rare.
• ICI-related: High-degree AV block can be the first manifestation of ICI myocarditis (rare 1%, mortality 50%). 17% of ICI cardiotoxicity patients had conduction disorders; associated with 80% vs. 16% cardiovascular mortality.
• Clinical pearl: AV-nodal blocking drugs have additive bradycardic effects with cancer therapeutics — consider prophylactic dose reduction before initiating bradycardic anticancer agents.

Autonomic Dysfunction in Cancer

• Autonomic dysfunction (AD) is more prevalent in cancer patients and survivors than healthy controls; most frequent in haematological malignancies.
• Manifestations: decreased heart rate variability, orthostatic hypotension, inappropriate sinus tachycardia, postural orthostatic tachycardia syndrome (POTS).
• Associated with increased fatigue, decreased exercise capacity, and increased mortality in Hodgkin lymphoma survivors and bone marrow transplant survivors.
• Contributing therapies: anthracyclines, taxanes, vinca alkaloids, platinum agents, head and neck irradiation, HSCT.
• Proposed mechanism: AD promotes inflammation and endothelial dysfunction → contributes to cancer survivor cardiovascular disease.
• Treatment options: Salt/fluid intake, leg elevation/compression; midodrine, fludrocortisone, pyridostigmine, droxidopa for orthostatic hypotension; ivabradine attractive option for inappropriate sinus tachycardia (data lacking — needs systematic evaluation).
• Structured aerobic exercise during/after cancer therapy has been shown to reverse AD in breast cancer patients and testicular cancer survivors.

Limitations of the Document

• Most evidence is from retrospective/observational studies and case series; no prospective RCTs specifically evaluating arrhythmia prevention or treatment in cancer patients.
• Incidence data are hampered by heterogeneous surveillance and reporting across studies — true incidence likely underestimated.
• Arrhythmia-related outcomes registries in cardio-oncology are lacking; existing registries (e.g. CARDIOTOX) do not currently include arrhythmias.
• Standard risk scores (CHA₂DS₂-VASc, HAS-BLED) have not been validated in cancer populations.

Key Concepts Mentioned

• concepts/Cardio-Oncology — umbrella framework
• concepts/Cancer-Therapy-Related-CV-Toxicity — drug-specific cardiotoxicity profiles
• concepts/Drug-Induced-Arrhythmia — QT prolongation and drug-induced TdP mechanisms
• concepts/Torsades-de-Pointes — QT-prolongation complication, management
• concepts/Cancer-Associated-Arrhythmia — central new concept
• concepts/Autonomic-Dysfunction-in-Cancer — new concept

Key Entities Mentioned

• entities/Atrial-Fibrillation — most common arrhythmia in cancer; cancer-specific management
• entities/Heart-Failure — chemotherapy-induced cardiomyopathy driving ICD/CRT
• entities/LMNA — conduction disease in cancer setting

Wiki Pages Updated

• wiki/sources/arrhythmia-cardio-oncology-aha-2021.md (created)
• wiki/concepts/Cancer-Associated-Arrhythmia.md (created)
• wiki/concepts/Autonomic-Dysfunction-in-Cancer.md (created)
• wiki/concepts/Cancer-Therapy-Related-CV-Toxicity.md (updated — arrhythmia section)
• wiki/concepts/Cardio-Oncology.md (updated — arrhythmia section)
• wiki/entities/Atrial-Fibrillation.md (updated — cancer-associated AF section)
• wiki/concepts/Torsades-de-Pointes.md (updated — cancer drug QT section)
• wiki/sourceindex.md (updated)
• wiki/wikiindex.md (updated)